Abbott Laboratories (ABT)vsPenumbra Inc (PEN)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
PEN
Penumbra Inc
$336.27
+0.63%
HEALTHCARE · Cap: $13.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 3058% more annual revenue ($44.33B vs $1.40B). ABT leads profitability with a 14.7% profit margin vs 12.7%. PEN appears more attractively valued with a PEG of 0.76. PEN earns a higher WallStSmart Score of 64/100 (C+).
ABT
Buy51
out of 100
Grade: C-
PEN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Margin of Safety
-60.3%
Fair Value
$211.07
Current Price
$336.27
$125.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Revenue surging 22.1% year-over-year
Earnings expanding 38.3% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
Trading at 9.2x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PEN
The strongest argument for PEN centers on Altman Z-Score, PEG Ratio, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : PEN
The primary concerns for PEN are Price/Book, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Key Dynamics to Monitor
ABT profiles as a value stock while PEN is a growth play — different risk/reward profiles.
PEN carries more volatility with a beta of 0.84 — expect wider price swings.
PEN is growing revenue faster at 22.1% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
PEN scores higher overall (64/100 vs 51/100) and 22.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Penumbra Inc
HEALTHCARE · MEDICAL DEVICES · USA
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?